To our knowledge, the relationship observed between MI and plasma NfL at baseline represents the first data in Huntington’s disease patients relating non-invasive 1H-MRS measures to an established biofluid marker of disease progression and further highlights the relationship between increased neuroinflammatory response and neurodegenerative processes in Huntington’s disease. This evidence concerns the gene NEFL and juvenile Huntington disease.